NURS 5432 Family Nurse Practitioner I Exam Study Guide | 2025–
2026 NURS 5432 FNP I Review Notes & Key Concepts | Exam
Guide 2025–2026
What’s Inside:
✅ Full breakdown of all FNP I modules (Module 1–6 or more)
✅ Key topics: health promotion, chronic disease, pediatrics, adult care, screenings,
diagnostics
✅ Clear definitions, summaries, and key points
✅ Clinical pearls and test-ready material
✅ Aligned with UTA and other accredited FNP programs
✅ Covers content needed for midterm and final exam success
🎯 Perfect For:
NURS 5432 students (University of Texas at Arlington or other FNP programs)
First-time exam takers or students needing a quick refresh
Visual learners who want organized notes instead of long lectures
FNP students preparing for clinical decision-making exams
Long-acting reversible contraception (LARC)
Effective birth control that lasts for years.
Tubal ligation
Surgical procedure for permanent birth control.
Menopause
12 months of amenorrhea in women over 40.
Perimenopause
Transition phase leading to menopause, lasts years.
DEXA scan
Bone density test to diagnose osteoporosis.
Hormone Replacement Therapy (HRT)
Treatment to alleviate menopausal symptoms with hormones.
,Non-hormonal medications
Alternatives for managing menopause symptoms without hormones.
Gabapentin
Medication used for hot flashes in menopause.
Clonidine
Medication for mild hot flashes, less effective than SSRIs.
Breast cancer risk
Increased risk associated with long-term hormone therapy.
VTE
Venous thromboembolism, a risk with hormone therapy.
Short term use
Increases CVD, cancer, VTE risks long term.
Tailored therapy
Achieve lowest dose for shortest duration.
Menopause onset
Introduce therapy early for better risk/benefit.
Absolute contraindications
None for hormone replacement therapy.
Estrogen-dependent malignancies
Includes breast, ovarian, and uterine cancers.
Unexplained uterine bleeding
Requires evaluation before hormone therapy.
History of VTE/CVA
Higher estrogen doses cause hypercoagulability.
Coronary artery disease (CAD)
Avoid estrogen for cardio-protective benefits.
Active liver disease
Higher estrogen doses may induce gallbladder disease.
Genitourinary Syndrome
, Includes vulvar/vaginal atrophy symptoms.
Topical estrogen therapy
Reverses vaginal atrophy, enhances blood flow.
Ospemifene
SERM for moderate to severe dyspareunia.
Estrogen and progesterone use
Depends on history of hysterectomy.
Fibroadenoma
Benign breast mass, smooth and rubbery.
Complex fibroadenoma
Includes cysts >3mm, sclerosing adenosis.
Fine needle aspiration biopsy
Used to rule out cancer in masses.
Fibrocystic breast disease
Common in premenopausal women, includes cysts.
Nipple discharge
Typically benign, requires surgical referral.
Galactorrhea
Physiologic discharge; check TSH and prolactin.
Breast cancer risk factors
Includes familial link, dense tissue, obesity.
Mammogram screening recommendations
USPSTF: 50-74 biennial; ACS: 45 annually.
SERMs
Tamoxifen and Raloxifene for breast cancer.
Ovarian cancer risk factors
Includes family history and BRCA mutations.
CA-125 tumor marker
Elevated in 90% of malignant nonmucinous tumors.
2026 NURS 5432 FNP I Review Notes & Key Concepts | Exam
Guide 2025–2026
What’s Inside:
✅ Full breakdown of all FNP I modules (Module 1–6 or more)
✅ Key topics: health promotion, chronic disease, pediatrics, adult care, screenings,
diagnostics
✅ Clear definitions, summaries, and key points
✅ Clinical pearls and test-ready material
✅ Aligned with UTA and other accredited FNP programs
✅ Covers content needed for midterm and final exam success
🎯 Perfect For:
NURS 5432 students (University of Texas at Arlington or other FNP programs)
First-time exam takers or students needing a quick refresh
Visual learners who want organized notes instead of long lectures
FNP students preparing for clinical decision-making exams
Long-acting reversible contraception (LARC)
Effective birth control that lasts for years.
Tubal ligation
Surgical procedure for permanent birth control.
Menopause
12 months of amenorrhea in women over 40.
Perimenopause
Transition phase leading to menopause, lasts years.
DEXA scan
Bone density test to diagnose osteoporosis.
Hormone Replacement Therapy (HRT)
Treatment to alleviate menopausal symptoms with hormones.
,Non-hormonal medications
Alternatives for managing menopause symptoms without hormones.
Gabapentin
Medication used for hot flashes in menopause.
Clonidine
Medication for mild hot flashes, less effective than SSRIs.
Breast cancer risk
Increased risk associated with long-term hormone therapy.
VTE
Venous thromboembolism, a risk with hormone therapy.
Short term use
Increases CVD, cancer, VTE risks long term.
Tailored therapy
Achieve lowest dose for shortest duration.
Menopause onset
Introduce therapy early for better risk/benefit.
Absolute contraindications
None for hormone replacement therapy.
Estrogen-dependent malignancies
Includes breast, ovarian, and uterine cancers.
Unexplained uterine bleeding
Requires evaluation before hormone therapy.
History of VTE/CVA
Higher estrogen doses cause hypercoagulability.
Coronary artery disease (CAD)
Avoid estrogen for cardio-protective benefits.
Active liver disease
Higher estrogen doses may induce gallbladder disease.
Genitourinary Syndrome
, Includes vulvar/vaginal atrophy symptoms.
Topical estrogen therapy
Reverses vaginal atrophy, enhances blood flow.
Ospemifene
SERM for moderate to severe dyspareunia.
Estrogen and progesterone use
Depends on history of hysterectomy.
Fibroadenoma
Benign breast mass, smooth and rubbery.
Complex fibroadenoma
Includes cysts >3mm, sclerosing adenosis.
Fine needle aspiration biopsy
Used to rule out cancer in masses.
Fibrocystic breast disease
Common in premenopausal women, includes cysts.
Nipple discharge
Typically benign, requires surgical referral.
Galactorrhea
Physiologic discharge; check TSH and prolactin.
Breast cancer risk factors
Includes familial link, dense tissue, obesity.
Mammogram screening recommendations
USPSTF: 50-74 biennial; ACS: 45 annually.
SERMs
Tamoxifen and Raloxifene for breast cancer.
Ovarian cancer risk factors
Includes family history and BRCA mutations.
CA-125 tumor marker
Elevated in 90% of malignant nonmucinous tumors.
